The Translational Cell and Tissue Regenerative Medicine Summit is your premiere forum to network with 80+ industry experts for the first time. Gain an unrivalled overview of the translational and clinical development landscape, and explore novel approaches to regenerate tissue topography through cell and tissue transplant.

Developed in collaboration with key research and clinical development teams from Organmet Bio, AstraZeneca, Sana Bio, Nestle Research, GC Therapeutics, Boehringer Ingelheim and more. Leave this meeting with key lessons learned to design therapies with clinical utility, and optimize CMC and manufacturing for safe, efficacious tissue therapies.

Read on go.evvnt.com

Understand Mechanism of Action, Maximize Efficacy and Therapeutic Window, and Evaluate Long-Term Clinical Outcomes of Fc Receptor Pathway Targeting Biologics in Autoantibody Mediated Disease.

The field of FcRn receptor targeting is gaining ground-breaking speed as Argenx, Janssen, UCB and Immunovant compete to tackle myasthenia gravis and biopharma invest in transformative immunological therapy for autoimmune diseases as the next big drug opportunity.

Read on go.evvnt.com

Accelerate Novel Lipid Discovery, Optimized Formulation and Tightened CQAs for Process Development to Achieve Scalability and Regulatory Compliance for Improved Product Quality and Widened Therapeutic Windows

Building on the success of our 2022 summit, we are bringing the inaugural LNP Formulation and Process Development Summit back and better than ever in 2023.

In April 2023, the 2nd Annual LNP Formulation and Process Development meeting is returning to Boston to welcome 350+ LNP Biology, Chemistry, Formulation and Process Development, Tech Ops and Manufacturing experts for sharing, learning and networking to turbocharge next generation of LNP development.

With expanded content, the 3-tracks summit will now offer the most comprehensive content, equipping you with end-to-end LNP development journey to exploit this lucrative non-viral delivery vehicle for various payloads to your destined cells and organs.

Join the ever-growing audience of LNP experts seeking to overcome the challenges of developing LNPs for a variety of applications and payloads, from discovery, formulation and process development, lipid supply and scale up manufacturing departments. 

Hear from likes of Omega Therapeutics, AstraZeneca, Pfizer, Beam Therapeutics, Alnylam Pharmaceuticals and more.

Group discounts and early booking rates are available. Please visit the website for full pricing information.

Read on go.evvnt.com

SAE Media Group is proud to announce the Inaugural Next Generation Genetic Vaccines Conference taking place on 20 - 21 March 2023, in London.

As part of SAE Media Group's leading series of conferences, this year's event will bring together expertise from individuals across the vaccine community. 

The two-day conference will offer a series of presentations, through which you will gain insight into the latest developments in advancing the pre-clinical and clinical translation of genetic vaccine development.

With COVID-19 leading to the rapid acceleration of the vaccines industry and a specific focus on genetic vaccines, the conference will consider the latest technologies and platforms such as mRNA being developed and utilised within the space. Integration of novel vaccine development into pre-clinical studies all the way to clinical will be covered, with case studies on applications in oncology and infectious diseases. 

This year's conference will also touch on how artificial intelligence can be used to transform vaccine research and development.

This event will not only bring you key insights you need to develop your gene-based vaccine pipeline, but it will also give you the opportunity to network with key players throughout the industry. 

Benefits of Attending:

• Discover the platforms and technologies being used across pharma and biotech for the development of gene-based vaccines
• Explore insights into early vaccine candidates and the integration of novel vaccine development approaches into pre-clinical and clinical studies
• Delve into the manufacturing considerations for the development of successful RNA vaccines
• Hear how artificial intelligence is being used to enhance vaccine R&D
• Consider the potential of genetic vaccines to target a variety of indications and diseases including cancer and infectious diseases

Read on go.evvnt.com

Register to learn how artificial intelligence can enable the identification of single cells without the wait times.

Read on xtalks.dryfta.com